Researchers at the University of California, Davis have developed a method for diagnosing an individual patient’s risk of inflammatory disease based on glycan profiling of high density lipoprotein (HDL). The resulting profile is then used to recommend a treatment program of dietary, lifestyle, or pharmaceutical interventions (or combination thereof), to improve health and decrease the risk of inflammation-induced disease by modulating the patient’s HDL glycosylation pattern.
High density lipoprotein (HDL) is known for its role in removing “bad cholesterol” and reducing the risk of heart disease. HDL has also been linked to inflammation and immune function. The functional capacity of HDL as it relates to its glycan composition however has never before been examined or characterized. This makes glycoprofiling of HDL proteins a potentially powerful tool for developing personalized biomarkers for the diagnosis and treatment of inflammatory diseases.
Researchers at the University of California, Davis have developed a method to diagnose an individual’s risk of inflammatory disease by measuring glycosylation levels of specific HDL proteins. Measurements from a patients’ blood sample are used to develop an HDL glycosylation profile that reflects the patient’s HDL’s immunomodulatory functional capacity. The profile values are then compared to control values representing healthy, and diseased populations, to assess the patient’s risk of inflammatory disease. A course of treatment (including diet, lifestyle, and other interventions) can then be recommended to positively alter the HDL glycan composition, improve HDL immunomodulatory function, and improve the patient’s health. This methodology breaks new ground by demonstrating a compositional aspect of HDL that is related to its immunomodulatory function, and applying that knowledge through a personalized approach to treating inflammatory disease.
|Patent Cooperation Treaty||Reference for National Filings||2018165574A1||09/13/2018||2017-562|
high density lipoprotein, HDL, inflammatory disease, glycan, glycosylation, immune modulation